Search Results
Your search for 3 matches 14919 pages
Showing 701 - 750Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology
Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
The National Cancer Act of 1971 Inspired a Career in Service to and Advocacy for Patients With Cancer
ASCO President for the 2024–2025 term, Robin Zon, MD, FACP, FASCO, was born and reared in Cheektowaga, a town in the western part of New York. “Cheektowaga is the Native American name for ‘land of the crabapple tree.’ Western New York was first settled by one of seven tribes belonging to the...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
FDA’s Crowdsourcing Initiative to Benefit Patient-Centric Clinical Trial Innovation
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) recently announced a new initiative called “Project 5 in 5.” Project 5 in 5 is a crowdsourcing initiative to ultimately identify five clinically relevant questions that can be answered through use of pragmatic...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
Advanced Ovarian Cancer: Adding Ruxolitinib to Front-Line Neoadjuvant Chemotherapy Plus Interval Debulking Surgery
In a phase I/II NRG Oncology Group study reported in the Journal of Clinical Oncology, Landen et al found that the addition of ruxolitinib to front-line paclitaxel/carboplatin neoadjuvant chemotherapy and interval debulking surgery improved progression-free survival in patients with stage III to IV ...
FDA Grants Accelerated Approval to Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Other Solid Tumors
On May 29, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the RET inhibitor selpercatinib (Retevmo) for pediatric patients aged 2 years and older with the following: Advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved...
Be Prepared: A Patient Perspective
I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
ASCO Issues Updated Guidelines for Stage IV NSCLC With and Without Driver Alterations
ASCO has issued new evidence-based updates to two living guidelines on the treatment of stage IV NSCLC with and without driver alterations.1,2 Updated Recommendations: Stage IV NSCLC With Driver Alterations The most “extensive work” in the updates occurred in the guideline on stage IV NSCLC with...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
A Look Back on an Impactful and Inspiring Presidential Year
Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...
KEYNOTE-564: Adjuvant Pembrolizumab Improves Overall Survival vs Placebo in Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown significant benefit with adjuvant...
We Have an IDEA: United in the Fight Against Cancer
On behalf of 2024 International Development and Education Award (IDEA) awardees, we received the decision of our acceptance in this outstanding training program offering mentorship and educational opportunities for early-career oncologists and cancer researchers with great interest. This will...
Partnering With Patients Is Integral for a Good Outcome
About 3 years ago, I woke up from a sound sleep and was having a hard time breathing. It felt like someone was sitting on my neck, constricting my airways. I could feel prominent swelling in my lymph nodes along my neck and clavicle, and I was scared. A trip to the emergency room proved fruitless, ...
Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers
Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...
Apply Through July 31, 2024, for Survivorship Champion’s Prize
Children’s Cancer Cause, a national advocacy group in pioneering research and innovation for pediatric cancer, announced it is accepting applications for the Survivorship Champion’s Prize. This award is presented to a group, program, or institution that has demonstrated significant advancements in...
ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK-Positive NSCLC
As reported in The New England Journal of Medicine by Yi‑Long Wu, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy...
Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer
As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...
Understanding the Legal and Ethical Challenges AI Poses in Oncology
The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...
Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the...
Most Breast Cancer Survivors Able to Achieve Pregnancy After Diagnosis, Study Finds
Research examining fertility preservation and pregnancy attempts among young women following a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. A new long-term study investigating fertility outcomes among young women who...
Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome
In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...
CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma
Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...
Study Finds the Financial Hardship Caused by Cancer Is Long-Lasting for Many Working-Age Adults
When combined with high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being unable to afford medical bills, distress and worry, or delaying or forgoing needed care because of cost, according to...
Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer
As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab was active in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer. As noted by the...
HPV Screening Intervals for Cervical Cancer May Be Safely Extended Beyond Current 5-Year Recommendation, Study Finds
A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...
Advanced Gastric or Gastroesophageal Junction Cancer: Addition of Relatlimab to Immunochemotherapy
In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...
Linvoseltamab Achieves High Response Rates in Relapsed or Refractory Myeloma
The investigational bispecific antibody linvoseltamab (targeting B-cell maturation antigen [BCMA] and CD3) achieved high response rates with acceptable safety in heavily pretreated patients with relapsed or refractory multiple myeloma, according to results of the phase I/II LINKER-MM1 study...
Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy in Resectable NSCLC: CheckMate 77T
As reported in The New England Journal of Medicine by Tina Cascone, MD, PhD, and colleagues, interim analysis in the phase III CheckMate 77T trial has shown that the addition of perioperative nivolumab to neoadjuvant chemotherapy improved event-free survival in patients with resectable non–small...
Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...
Pertuzumab Plus Trastuzumab for Advanced Biliary Tract Cancer With HER2/3 Alterations
As reported in the Journal of Clinical Oncology by Cannon et al, findings in a cohort of the phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study showed that the combination of pertuzumab and trastuzumab was active in patients with advanced biliary tract cancer with...
NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?
Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents
In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, for patients with extensive-stage small cell lung cancer (SCLC) with disease progression on or after...
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic...
Third-Line Therapy for Transplant-Ineligible DLBCL
This is Part 3 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the third-line treatment of...
AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities
Despite the extraordinary progress against cancer in the United States—illustrated by the continuing decline in the overall mortality rate, which fell by 33% between 1991 and 2020, and the increasing numbers of cancer survivors (over 18 million and climbing)—the burden of cancer remains...
Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT
As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...
T-DXd for Advanced Solid Tumors With Activating HER2 Mutations
As reported in The Lancet Oncology by Bob T. Li, MD, PhD, MPH, and colleagues, the phase II DESTINY-PanTumor01 trial showed activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with unresectable or metastatic solid tumors that have specific activating HER2 mutations. The antibody-drug...
Doublet for Previously Treated Patients With Advanced Leiomyosarcoma
In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. Unesbulin is a small...
Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
